?Founded in 2001, Pluristem Therapeutics is a bio-therapeutics company that lists on the NASDAQ Capital Market. The Company is dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic, and autoimmune disorders. The (PLacental eXpanded) cell products are stored off-the-shelf, ready-to-use, and require no histocompatibility matching.
Pluristem Therapeutics Inc. has made the strategic decision to work only with adult stem cells, purified from the placenta after birth, avoiding ethical and religious controversy. The placental adherent stromal cells (ASCs) are expanded in the Company’s proprietary PluriX™ 3D bioreactor system.
This system provides a 3D microenvironment that enables large-scale growth of these cells without the need for supplemental growth factors or other exogenous materials. ASCs are multipotent adult stem cells that have strong anti-inflammatory properties and can regenerate and repair damaged tissue.
PLX cells are the ASCs expanded in Pluristem’s proprietary (PluriX™) 3D bioreactor. PLX cells are immune privileged, possess immunomodulatory properties, and are expanded in vitro without showing signs of phenotypic or karyotypic changes. Pluristem Therapeutics believes that the PLX cells’ mechanism of action may be related to the secretion of cytokines and/or other potent immune modulators.
The Company’s first product, PLX-PAD, is designed to treat Peripheral Artery Disease. PLX-PAD received from the Food and Drug Administration (FDA) and the Paul Ehrlich Institute (PEI), the German competent authority in the European Union, clearance to begin a “First-In-Human” placental-derived mesenchymal-like stromal cell clinical trial.
PLX-PAD has undergone development as an unrelated donor-patient (allogeneic) product intended to treat the limb ischemia from Peripheral Artery Disease (PAD). In the United States alone, it is estimated that 8 to 12 million people suffer from limb ischemia.
Pluristem Therapeutics Inc.’s pre-clinical product line-up includes PLX-IBD for inflammatory bowel diseases; PLX-STROKE for ischemic strokes; PLX-BMT for bone marrow transplantation; and PLX-MS for multiple sclerosis.